Smartstream Research Reveals Five Realities Redefining Buy-Side Reconciliations
22.4.2026 11:05:00 EEST | Business Wire | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces new findings from its latest industry research report, Smart Reconciliations: The Buy-Side Perspective, highlighting the structural shifts transforming reconciliation, control, and operational confidence across buy-side firms.
Based on insights gathered from a roundtable of senior operations leaders across asset management and investment firms, the report identifies five critical realities reshaping reconciliation strategies. Despite widespread awareness of rising operational risk, many firms remain constrained by fragmented, reactive, and legacy-driven models.
Buy-side reconciliations is undergoing a fundamental transformation driven by multi-asset expansion, compressed settlement cycles such as T+1, increasing regulatory scrutiny, and growing reliance on third-party providers. These forces are exposing the limitations of traditional batch-based approaches.
The research reveals that over 70% of buy-side firms rely primarily on end-of-day reconciliation, while 53% cite timing differences and data mismatches as the leading causes of breaks. Data quality and availability remain the single largest barriers to achieving effective intraday control.
The five realities shaping buy-side reconciliations:
1. Data integrity risk extends beyond the enterprise
Firms face their greatest data challenges across a complex ecosystem of custodians, brokers, and administrators. 59% of participants identified external data dependencies as the primary risk, while 47% highlighted internal inconsistencies. Incomplete and insufficiently enriched data continues to compound reconciliations pressure, directly impacting liquidity decisions, NAV accuracy, regulatory reporting, and client confidence.
2. T+1 settlement is a systemic stress test
The move to T+1 has transformed reconciliations into a time-critical control function. While 69% of banks report partially adapted models, significant gaps remain in intraday visibility and exception resolution. The result is increased operational risk, particularly in funding and liquidity management.
3. Batch reconciliations is no longer sufficient
Traditional batch processes are increasingly misaligned with today’s transaction complexity and settlement velocity. Only 18% of firms operate near real-time or intraday controls, leaving the majority exposed to late-stage risk and compressed remediation windows. And 53% report rising data mismatches.
4. Third-party oversight remains fragmented
As reliance on external providers grows, accountability and visibility are becoming more opaque. 44% of firms report no significant evolution in oversight models, while data consistency across parties remains the dominant challenge. Leading firms are moving toward independent validation frameworks with full auditability and governance.
5. Efficiency gains depend on data, automation, and AI
Automation is emerging as the primary driver of efficiency, with 62% of firms prioritising a single source of truth. However, sustainable transformation requires more than layering automation onto legacy systems. Firms must first consolidate, normalise, and enrich data to unlock the full value of AI-driven reconciliation and workflow optimisation.
The report highlights a clear shift in leading firms toward repositioning reconciliations as an ‘always-on’ control layer rather than a retrospective, end-of-day checkpoint. This approach enables earlier risk detection, faster decision-making, and stronger operational resilience.
Robin Hasson, Product Management, Smartstream, says: “As buy-side firms navigate increasing complexity and tighter timelines, the ability to establish trusted data foundations and real-time control frameworks is becoming a competitive differentiator. Our report highlights the urgent need for firms to modernise reconciliation strategies to meet the demands of a rapidly evolving financial landscape.”
ABOUT SMARTSTREAM
Smartstream unlocks trusted, intelligent data insights – clearly, consistently, and without compromise.
Empowering leading global financial institutions and enterprises with innovative solutions that deliver accurate, timely data insights to streamline operations, reduce costs, and meet regulatory demands with confidence.
By harnessing data at the core of customer operations, Smartstream drives smarter, faster outcomes across reconciliations, liquidity, collateral, corporate actions, fees, and reference data solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260422712463/en/
Contacts
Shamira Alidina
Media Relations Director
Dina Communications
Email: shamira@dinacomms.com
Nathan Gee
Global Head of Marketing
Smartstream
Email: nathan.gee@smartstream-stp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom